Clinical efficacy of methylprednisolone sodium succinate with different administration modes in the treatment of sudden sensorin eural hearing loss

ObjectiveTo investigate the therapeutic effect of methylprednisolone sodium succinate on sudden sensorin eural hearing loss.

MethodsA total of 322 patients with sudden sensorin eural hearing loss were divided into intravenous methylprednisolone sodium succinate group(group A, n=208), intratympanic injection of methylprednisolone sodium succinate group(group B, n=114) and intratympanic injection of methylprednisolone sodium succinate group(group C, n=67).The hearing threshold, therapeutic effect and adverse reaction rate among the three groups were compared, and the influence of basic disease on the therapeutic effect was analyzed.

ResultsThere was no significant difference in hearing threshold among the three groups before treatment(P>0.05).After treatment, the hearing threshold was significantly lower than that before treatment(P < 0.01), and the hearing threshold in group A and group B was lower than that in group C(P < 0.05).The total effective rate in group A and group B was higher than that in group C(P < 0.05), but there was no significant difference between group A and group B(P>0.05).The total adverse reaction rate in group B was significantly lower than that in group A and group C(P < 0.01).The total effective rate in group without basic disease was significantly higher than that in group with basic disease(P < 0.01).

ConclusionsIntratympanic injection therapy is better than intravenous therapy.The type and degree of hearing loss and basic disease have great impacts on the prognosis.Therefore, it is necessary to evaluate the patient's condition in detail for taking reasonable treatment method.